vs
HAEMONETICS CORP（HAE）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是HAEMONETICS CORP的2.6倍（$906.4M vs $346.4M），HAEMONETICS CORP净利率更高（28.1% vs 11.9%，领先16.2%），Rollins, Inc.同比增速更快（10.2% vs 4.8%），HAEMONETICS CORP自由现金流更多（$209.9M vs $111.2M），过去两年HAEMONETICS CORP的营收复合增速更高（1.5% vs 0.8%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
HAE vs ROL — 直观对比
营收规模更大
ROL
是对方的2.6倍
$346.4M
营收增速更快
ROL
高出5.4%
4.8%
净利率更高
HAE
高出16.2%
11.9%
自由现金流更多
HAE
多$98.7M
$111.2M
两年增速更快
HAE
近两年复合增速
0.8%
损益表 — Q4 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $346.4M | $906.4M |
| 净利润 | $97.3M | $107.8M |
| 毛利率 | 57.2% | — |
| 营业利润率 | 36.1% | 16.1% |
| 净利率 | 28.1% | 11.9% |
| 营收同比 | 4.8% | 10.2% |
| 净利润同比 | — | 2.5% |
| 每股收益（稀释后） | — | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAEROL
| Q1 26 | $346.4M | $906.4M | ||
| Q4 25 | $339.0M | $912.9M | ||
| Q3 25 | $327.3M | $1.0B | ||
| Q2 25 | $321.4M | $999.5M | ||
| Q1 25 | $330.6M | $822.5M | ||
| Q4 24 | $348.5M | $832.2M | ||
| Q3 24 | $345.5M | $916.3M | ||
| Q2 24 | $336.2M | $891.9M |
净利润HAEROL
| Q1 26 | $97.3M | $107.8M | ||
| Q4 25 | $44.7M | $116.4M | ||
| Q3 25 | $38.7M | $163.5M | ||
| Q2 25 | $34.0M | $141.5M | ||
| Q1 25 | $58.0M | $105.2M | ||
| Q4 24 | $37.5M | $105.7M | ||
| Q3 24 | $33.8M | $136.9M | ||
| Q2 24 | $38.4M | $129.4M |
毛利率HAEROL
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — |
营业利润率HAEROL
| Q1 26 | 36.1% | 16.1% | ||
| Q4 25 | 19.9% | 17.5% | ||
| Q3 25 | 17.9% | 21.9% | ||
| Q2 25 | 16.8% | 19.8% | ||
| Q1 25 | 21.6% | 17.3% | ||
| Q4 24 | 16.9% | 18.1% | ||
| Q3 24 | 15.0% | 20.9% | ||
| Q2 24 | 11.8% | 20.4% |
净利率HAEROL
| Q1 26 | 28.1% | 11.9% | ||
| Q4 25 | 13.2% | 12.8% | ||
| Q3 25 | 11.8% | 15.9% | ||
| Q2 25 | 10.6% | 14.2% | ||
| Q1 25 | 17.5% | 12.8% | ||
| Q4 24 | 10.8% | 12.7% | ||
| Q3 24 | 9.8% | 14.9% | ||
| Q2 24 | 11.4% | 14.5% |
每股收益（稀释后）HAEROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $0.95 | $0.24 | ||
| Q3 25 | $0.81 | $0.34 | ||
| Q2 25 | $0.70 | $0.29 | ||
| Q1 25 | $1.17 | $0.22 | ||
| Q4 24 | $0.74 | $0.22 | ||
| Q3 24 | $0.66 | $0.28 | ||
| Q2 24 | $0.74 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $245.4M | $116.5M |
| 总债务越低越好 | $1.2B | $650.6M |
| 股东权益账面价值 | $796.3M | $1.4B |
| 总资产 | $2.4B | $3.2B |
| 负债/权益比越低杠杆越低 | 1.53× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资HAEROL
| Q1 26 | $245.4M | $116.5M | ||
| Q4 25 | $363.4M | $100.0M | ||
| Q3 25 | $296.4M | $127.4M | ||
| Q2 25 | $292.9M | $123.0M | ||
| Q1 25 | $306.8M | $201.2M | ||
| Q4 24 | $320.8M | $89.6M | ||
| Q3 24 | $299.3M | $95.3M | ||
| Q2 24 | $344.4M | $106.7M |
总债务HAEROL
| Q1 26 | $1.2B | $650.6M | ||
| Q4 25 | $1.2B | $486.1M | ||
| Q3 25 | $1.2B | $485.7M | ||
| Q2 25 | $1.2B | $485.3M | ||
| Q1 25 | $1.2B | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益HAEROL
| Q1 26 | $796.3M | $1.4B | ||
| Q4 25 | $911.5M | $1.4B | ||
| Q3 25 | $849.2M | $1.5B | ||
| Q2 25 | $882.3M | $1.4B | ||
| Q1 25 | $820.8M | $1.4B | ||
| Q4 24 | $906.9M | $1.3B | ||
| Q3 24 | $878.9M | $1.3B | ||
| Q2 24 | $905.4M | $1.2B |
总资产HAEROL
| Q1 26 | $2.4B | $3.2B | ||
| Q4 25 | $2.5B | $3.1B | ||
| Q3 25 | $2.4B | $3.2B | ||
| Q2 25 | $2.5B | $3.2B | ||
| Q1 25 | $2.5B | $2.9B | ||
| Q4 24 | $2.5B | $2.8B | ||
| Q3 24 | $2.5B | $2.8B | ||
| Q2 24 | $2.5B | $2.8B |
负债/权益比HAEROL
| Q1 26 | 1.53× | 0.47× | ||
| Q4 25 | 1.34× | 0.35× | ||
| Q3 25 | 1.44× | 0.32× | ||
| Q2 25 | 1.39× | 0.34× | ||
| Q1 25 | 1.49× | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $293.2M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $209.9M | $111.2M |
| 自由现金流率自由现金流/营收 | 60.6% | 12.3% |
| 资本支出强度资本支出/营收 | 9.5% | 0.8% |
| 现金转化率经营现金流/净利润 | 3.01× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $417.1M | $621.1M |
8季度趋势，按日历期对齐
经营现金流HAEROL
| Q1 26 | $293.2M | $118.4M | ||
| Q4 25 | $93.6M | $164.7M | ||
| Q3 25 | $111.3M | $191.3M | ||
| Q2 25 | $17.4M | $175.1M | ||
| Q1 25 | $116.6M | $146.9M | ||
| Q4 24 | $43.8M | $188.2M | ||
| Q3 24 | $48.8M | $146.9M | ||
| Q2 24 | $-27.4M | $145.1M |
自由现金流HAEROL
| Q1 26 | $209.9M | $111.2M | ||
| Q4 25 | $87.2M | $159.0M | ||
| Q3 25 | $106.3M | $182.8M | ||
| Q2 25 | $13.6M | $168.0M | ||
| Q1 25 | $100.9M | $140.1M | ||
| Q4 24 | $35.2M | $184.0M | ||
| Q3 24 | $39.4M | $139.4M | ||
| Q2 24 | $-33.1M | $136.4M |
自由现金流率HAEROL
| Q1 26 | 60.6% | 12.3% | ||
| Q4 25 | 25.7% | 17.4% | ||
| Q3 25 | 32.5% | 17.8% | ||
| Q2 25 | 4.2% | 16.8% | ||
| Q1 25 | 30.5% | 17.0% | ||
| Q4 24 | 10.1% | 22.1% | ||
| Q3 24 | 11.4% | 15.2% | ||
| Q2 24 | -9.8% | 15.3% |
资本支出强度HAEROL
| Q1 26 | 9.5% | 0.8% | ||
| Q4 25 | 1.9% | 0.6% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 1.2% | 0.7% | ||
| Q1 25 | 4.7% | 0.8% | ||
| Q4 24 | 2.5% | 0.5% | ||
| Q3 24 | 2.7% | 0.8% | ||
| Q2 24 | 1.7% | 1.0% |
现金转化率HAEROL
| Q1 26 | 3.01× | 1.10× | ||
| Q4 25 | 2.09× | 1.41× | ||
| Q3 25 | 2.88× | 1.17× | ||
| Q2 25 | 0.51× | 1.24× | ||
| Q1 25 | 2.01× | 1.40× | ||
| Q4 24 | 1.17× | 1.78× | ||
| Q3 24 | 1.44× | 1.07× | ||
| Q2 24 | -0.71× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
ROL
暂无分部数据
